Pulmonary arterial hypertension.
McLaughlin
Vallerie V
VV
University of Michigan Health System, Ann Arbor, MI 48109-0273, USA. vmclaugh@umich.edu
McGoon
Michael D
MD
D000465:Algorithms; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D006328:Cardiac Catheterization; D004232:Diuretics / Q000627:therapeutic use; D004617:Embolism / Q000150:complications; D065128:Endothelin Receptor Antagonists; D017079:Exercise Tolerance; D020022:Genetic Predisposition to Disease; D006331:Heart Diseases / Q000150:complications; D006801:Humans; D006976:Hypertension, Pulmonary / Q000145:classification / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D000860:Hypoxia / Q000150:complications; D008019:Life Style; D008171:Lung Diseases / Q000150:complications; D016040:Lung Transplantation; D008954:Models, Biological; D044062:Prostaglandins I / Q000627:therapeutic use; D014655:Vascular Resistance; D014665:Vasodilator Agents / Q000494:pharmacology / Q000627:therapeutic use
D002121:Calcium Channel Blockers; D004232:Diuretics; D065128:Endothelin Receptor Antagonists; D044062:Prostaglandins I; D014665:Vasodilator Agents